Related Experiment Video
Updated: May 29, 2026

Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
Access to advanced therapy medicinal products in the EU: where do we stand?
1INSERM UMRS 1027, Université de Toulouse, Université Paul Sabatier - Toulouse III, France. mahalat@cict.fr
Abstract:
The European Union has a public health strategy and will generally ensure in all its policies and activities a "high level of human health protection". The new Regulation (EC) n 1394/2007 on advanced therapy medicinal products (ATMP), stems from this global policy and aims to harmonise access to the ATMP market. A real will for the harmonisation is clearly expressed in legal texts and enforced in the implementable procedures and requirements. However, several barriers remain. On the one hand, the scope of the ATMP Regulation is limited. On the other hand, Member States benefit from a wide margin of action.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
FDA Approved Drugs: Changes to Approved Drugs
Clinical Trials: Overview
Preclinical Development: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Therapeutic Drug Monitoring: Drug Analysis Methods

